POERIO, ANGELA
POERIO, ANGELA
DIPARTIMENTO DI EMATOLOGIA E SCIENZE ONCOLOGICHE "L. e A. SERAGNOLI"
POERIO A.; A. Poerio
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
2006 IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFUSCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia
2006 Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML)
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib
2004 SOVERINI S; MARTINELLI G.; AMABILE M; POERIO A; BIANCHINI M; ROSTI G; PANE F; SAGLIO G; BACCARANI M.
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience
2009 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
2008 Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
2004 BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S.; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP.
2005 Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; Ottaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
2008 Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML.
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia
2009 Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
2009 Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party.
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
2009 Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M.
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
2011 Soverini S; Vitale A; Poerio A; Gnani A; Colarossi S; Iacobucci I; Cimino G; Elia L; Lonetti A; Vignetti M; Paolini S; Meloni G; di Maio V; Papayannidis C; Amabile M; Guarini A; Baccarani M; Martinelli G; Foa' R
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
2009 Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G.
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
2010 Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
2009 Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagn...etti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M. | 2005-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. | IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFU...SCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia | Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruz...zese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML) | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib | SOVERINI S; MARTINELLI G.; AMABILE M; POERIO A; BIANCHINI M; ROSTI G; PANE F; SAGLIO G; BACCARANI M. | 2004-01-01 | CLINICAL CHEMISTRY | - | 1.01 Articolo in rivista | - |
| Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni | 2009-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome | Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T,... Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia | BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S....; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA | 2004-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. | Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; O...ttaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G | 2005-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. | Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F;... De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia | Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; ...Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni | 2009-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. | Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava ...C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure | Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; ...Rosti G; Baccarani M. | 2009-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis | Soverini S; Vitale A; Poerio A; Gnani A; Colarossi S; Iacobucci I; Cimino G; Elia L; Lonetti A; V...ignetti M; Paolini S; Meloni G; di Maio V; Papayannidis C; Amabile M; Guarini A; Baccarani M; Martinelli G; Foa' R | 2011-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. | Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de... Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. | Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N...; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M | 2010-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response | Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Re...ge-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |